Gilead Sciences annual net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Net Income Growth & History (GILD)
Gilead Sciences's net income was $8.51B for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.51B | $8.03B | +1672.92% |
| 2024 | 2024-12-31 | $480.0M | −$5.18B | −91.53% |
| 2023 | 2023-12-31 | $5.67B | $1.07B | +23.37% |
| 2022 | 2022-12-31 | $4.59B | −$1.63B | −26.23% |
| 2021 | 2021-12-31 | $6.22B | $6.10B | +4960.98% |
| 2020 | 2020-12-31 | $123.0M | −$5.26B | −97.72% |
| 2019 | 2019-12-31 | $5.39B | −$69.0M | −1.26% |
| 2018 | 2018-12-31 | $5.46B | $827.0M | +17.87% |
| 2017 | 2017-12-31 | $4.63B | −$8.87B | −65.72% |
| 2016 | 2016-12-31 | $13.50B | −$4.61B | −25.44% |
| 2015 | 2015-12-31 | $18.11B | $6.01B | +49.64% |
| 2014 | 2014-12-31 | $12.10B | $9.03B | +293.53% |
| 2013 | 2013-12-31 | $3.08B | $483.0M | +18.63% |
| 2012 | 2012-12-31 | $2.59B | −$211.6M | −7.55% |
| 2011 | 2011-12-31 | $2.80B | −$97.6M | −3.36% |
| 2010 | 2010-12-31 | $2.90B | $265.5M | +10.07% |
| 2009 | 2009-12-31 | $2.64B | $656.9M | +33.19% |
| 2008 | 2008-12-31 | $1.98B | $394.0M | +24.86% |
| 2007 | 2007-12-31 | $1.58B | — | — |
Gilead Sciences quarterly net income
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$10.50B | −$12.46B | — |
| Q1 2026 | 2026-03-31 | $2.02B | $706.0M | +53.69% |
| Q4 2025 | 2025-12-31 | $2.18B | $400.0M | +22.43% |
| Q3 2025 | 2025-09-30 | $3.05B | $1.80B | +143.58% |
| Q2 2025 | 2025-06-30 | $1.96B | $346.0M | +21.44% |
| Q1 2025 | 2025-03-31 | $1.31B | $5.49B | — |
| Q4 2024 | 2024-12-31 | $1.78B | $353.0M | +24.69% |
| Q3 2024 | 2024-09-30 | $1.25B | −$927.0M | −42.52% |
| Q2 2024 | 2024-06-30 | $1.61B | $569.0M | +54.45% |
| Q1 2024 | 2024-03-31 | −$4.17B | −$5.18B | — |
| Q4 2023 | 2023-12-31 | $1.43B | −$210.0M | −12.80% |
| Q3 2023 | 2023-09-30 | $2.18B | $391.0M | +21.86% |
| Q2 2023 | 2023-06-30 | $1.04B | −$99.0M | −8.65% |
| Q1 2023 | 2023-03-31 | $1.01B | $991.0M | +5215.79% |
| Q4 2022 | 2022-12-31 | $1.64B | $1.26B | +329.32% |
| Q3 2022 | 2022-09-30 | $1.79B | −$803.0M | −30.98% |
| Q2 2022 | 2022-06-30 | $1.14B | −$378.0M | −24.84% |
| Q1 2022 | 2022-03-31 | $19.0M | −$1.71B | −98.90% |
| Q4 2021 | 2021-12-31 | $382.0M | −$1.17B | −75.37% |
| Q3 2021 | 2021-09-30 | $2.59B | $2.23B | +620.00% |
| Q2 2021 | 2021-06-30 | $1.52B | $4.86B | — |
| Q1 2021 | 2021-03-31 | $1.73B | $178.0M | +11.48% |
| Q4 2020 | 2020-12-31 | $1.55B | −$1.15B | −42.47% |
| Q3 2020 | 2020-09-30 | $360.0M | $1.52B | — |
| Q2 2020 | 2020-06-30 | −$3.34B | −$5.22B | — |
| Q1 2020 | 2020-03-31 | $1.55B | −$424.0M | −21.47% |
| Q4 2019 | 2019-12-31 | $2.70B | $2.69B | +89766.67% |
| Q3 2019 | 2019-09-30 | −$1.17B | −$3.26B | — |
| Q2 2019 | 2019-06-30 | $1.88B | $63.0M | +3.47% |
| Q1 2019 | 2019-03-31 | $1.98B | $437.0M | +28.41% |
| Q4 2018 | 2018-12-31 | $3.0M | $3.87B | — |
| Q3 2018 | 2018-09-30 | $2.10B | −$621.0M | −22.85% |
| Q2 2018 | 2018-06-30 | $1.82B | −$1.26B | −40.87% |
| Q1 2018 | 2018-03-31 | $1.54B | −$1.16B | −43.08% |
| Q4 2017 | 2017-12-31 | −$3.87B | −$6.97B | — |
| Q3 2017 | 2017-09-30 | $2.72B | −$612.0M | −18.38% |
| Q2 2017 | 2017-06-30 | $3.07B | −$424.0M | −12.12% |
| Q1 2017 | 2017-03-31 | $2.70B | −$864.0M | −24.23% |
| Q4 2016 | 2016-12-31 | $3.11B | −$1.57B | −33.63% |
| Q3 2016 | 2016-09-30 | $3.33B | −$1.27B | −27.61% |
| Q2 2016 | 2016-06-30 | $3.50B | −$995.0M | −22.15% |
| Q1 2016 | 2016-03-31 | $3.57B | −$767.0M | −17.70% |
| Q4 2015 | 2015-12-31 | $4.68B | $1.20B | +34.30% |
| Q3 2015 | 2015-09-30 | $4.60B | $1.87B | +68.44% |
| Q2 2015 | 2015-06-30 | $4.49B | $836.0M | +22.87% |
| Q1 2015 | 2015-03-31 | $4.33B | $2.11B | +94.57% |
| Q4 2014 | 2014-12-31 | $3.49B | $2.70B | +340.83% |
| Q3 2014 | 2014-09-30 | $2.73B | $1.94B | +246.13% |
| Q2 2014 | 2014-06-30 | $3.66B | $2.88B | +372.96% |
| Q1 2014 | 2014-03-31 | $2.23B | $1.50B | +208.45% |
| Q4 2013 | 2013-12-31 | $791.0M | $28.5M | +3.73% |
| Q3 2013 | 2013-09-30 | $789.0M | $113.5M | +16.80% |
| Q2 2013 | 2013-06-30 | $773.0M | $61.4M | +8.63% |
| Q1 2013 | 2013-03-31 | $722.0M | $280.0M | +63.36% |
| Q4 2012 | 2012-12-31 | $762.5M | $97.4M | +14.64% |
| Q3 2012 | 2012-09-30 | $675.5M | $233.5M | +52.84% |
| Q2 2012 | 2012-06-30 | $711.6M | −$34.7M | −4.65% |
| Q1 2012 | 2012-03-31 | $442.0M | −$209.2M | −32.13% |
| Q4 2011 | 2011-12-31 | $665.1M | $35.7M | +5.68% |
| Q3 2011 | 2011-09-30 | $442.0M | −$262.9M | −37.30% |
| Q2 2011 | 2011-06-30 | $746.2M | $34.2M | +4.80% |
| Q1 2011 | 2011-03-31 | $651.1M | −$203.8M | −23.83% |
| Q4 2010 | 2010-12-31 | $629.4M | −$172.8M | −21.54% |
| Q3 2010 | 2010-09-30 | $704.9M | $31.8M | +4.73% |
| Q2 2010 | 2010-06-30 | $712.1M | $140.7M | +24.62% |
| Q1 2010 | 2010-03-31 | $854.9M | $265.8M | +45.12% |
| Q4 2009 | 2009-12-31 | $802.2M | — | — |
| Q3 2009 | 2009-09-30 | $673.0M | $177.2M | +35.73% |
| Q2 2009 | 2009-06-30 | $571.4M | $136.6M | +31.42% |
| Q1 2009 | 2009-03-31 | $589.1M | — | — |
| Q3 2008 | 2008-09-30 | $495.9M | — | — |
| Q2 2008 | 2008-06-30 | $434.8M | — | — |
Gilead Sciences net income trends
Over the last five fiscal years, Gilead Sciences's net income increased from $123.0M to $8.51B, a change of $8.39B. The latest reported quarter, Q2 2026, shows −$10.50B.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
